Regions Financial Corp’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.39M Buy
28,929
+7,392
+34% +$318K 0.01% 440
2026
Q1
$791K Sell
21,537
-7,466
-26% -$354K 0.01% 524
2025
Q4
$1.48M Buy
29,003
+9,150
+46% +$468K 0.01% 429
2025
Q3
$1.1M Sell
19,853
-16,589
-46% -$971K 0.01% 482
2025
Q2
$2.52M Sell
36,442
-8,615
-19% -$586K 0.02% 346
2025
Q1
$3.13M Buy
45,057
+800
+2% +$66.1K 0.02% 286
2024
Q4
$3.81M Sell
44,257
-1,165
-3% -$126K 0.03% 257
2024
Q3
$5.41M Buy
45,422
+5,173
+13% +$690K 0.04% 225
2024
Q2
$5.75M Sell
40,249
-3,687
-8% -$489K 0.04% 209
2024
Q1
$5.64M Sell
43,936
-2,506
-5% -$298K 0.04% 216
2023
Q4
$4.8M Buy
46,442
+322
+0.7% +$31.8K 0.04% 230
2023
Q3
$4.19M Buy
46,120
+12,224
+36% +$1.08M 0.04% 232
2023
Q2
$2.74M Buy
33,896
+17,730
+110% +$1.45M 0.02% 301
2023
Q1
$1.29M Buy
16,166
+3,182
+25% +$226K 0.01% 430
2022
Q4
$878K Sell
12,984
-1,020
-7% -$59.8K 0.01% 506
2022
Q3
$698K Sell
14,004
-18
-0.1% -$964 0.01% 524
2022
Q2
$781K Buy
14,022
+1,118
+9% +$62K 0.01% 517
2022
Q1
$716K Sell
12,904
-292
-2% -$15K 0.01% 563
2021
Q4
$739K Sell
13,196
-1,000
-7% -$54.2K 0.01% 557
2021
Q3
$682K Sell
14,196
-730
-5% -$35.3K 0.01% 559
2021
Q2
$625K Buy
14,926
+5,746
+63% +$223K 0.01% 559
2021
Q1
$309K Buy
9,180
+202
+2% +$7.2K ﹤0.01% 706
2020
Q4
$313K Sell
8,978
-16,956
-65% -$586K ﹤0.01% 668
2020
Q3
$900K Buy
25,934
+1,192
+5% +$39.7K 0.01% 434
2020
Q2
$810K Buy
24,742
+374
+2% +$11.9K 0.01% 442
2020
Q1
$734K Sell
24,368
-2,622
-10% -$78.1K 0.01% 437
2019
Q4
$781K Buy
26,990
+602
+2% +$16.7K 0.01% 467
2019
Q3
$682K Buy
26,388
+696
+3% +$17.6K 0.01% 472
2019
Q2
$656K Buy
25,692
+1,638
+7% +$40.5K 0.01% 478
2019
Q1
$629K Sell
24,054
-1,672
-6% -$41.1K 0.01% 496
2018
Q4
$593K Sell
25,726
-2,042
-7% -$45.4K 0.01% 481
2018
Q3
$654K Sell
27,768
-13,958
-33% -$341K 0.01% 499
2018
Q2
$962K Sell
41,726
-128
-0.3% -$3.04K 0.01% 423
2018
Q1
$1.03M Sell
41,854
-9,240
-18% -$243K 0.01% 415
2017
Q4
$1.37M Buy
51,094
+3,946
+8% +$100K 0.01% 378
2017
Q3
$1.14M Buy
47,148
+3,296
+8% +$74.5K 0.01% 410
2017
Q2
$941K Buy
43,852
+2,226
+5% +$44.9K 0.01% 449
2017
Q1
$714K Buy
41,626
+14,568
+54% +$254K 0.01% 581
2016
Q4
$485K Sell
27,058
-1,266
-4% -$23K 0.01% 660
2016
Q3
$589K Sell
28,324
-26,936
-49% -$668K 0.01% 617
2016
Q2
$1.49M Sell
55,260
-688
-1% -$18.9K 0.02% 378
2016
Q1
$1.52M Buy
55,948
+2,824
+5% +$75.7K 0.02% 389
2015
Q4
$1.54M Sell
53,124
-1,124
-2% -$31.1K 0.02% 384
2015
Q3
$1.47M Buy
54,248
+8,088
+18% +$229K 0.02% 391
2015
Q2
$1.26M Buy
46,160
+1,806
+4% +$50.8K 0.02% 447
2015
Q1
$1.18M Buy
44,354
+8,308
+23% +$191K 0.02% 471
2014
Q4
$763K Buy
36,046
+2,942
+9% +$65.7K 0.01% 577
2014
Q3
$788K Sell
33,104
-72
-0.2% -$1.66K 0.01% 661
2014
Q2
$766K Sell
33,176
-610
-2% -$13.5K 0.01% 681
2014
Q1
$771K Sell
33,786
-4,184
-11% -$89.1K 0.01% 665
2013
Q4
$701K Buy
37,970
+5,290
+16% +$92.2K 0.01% 673
2013
Q3
$553K Buy
32,680
+2,290
+8% +$38.5K 0.01% 714
2013
Q2
$471K Buy
+30,390
New +$506K 0.01% 735

Other funds holding NVO

Regions Financial Corp's NVO Position: Q2 2026 in Review

Regions Financial Corp increased its Novo Nordisk (NVO) stake by 34% in Q2 2026, buying an estimated $318K and bringing the position to 28,929 shares worth $1.39M. The position accounts for 0.01% of the portfolio, ranked #440.

Regions Financial Corp first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.75M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Regions Financial Corp held 28,929 shares of Novo Nordisk worth $1.39M as of Q2 2026.
  • Regions Financial Corp bought 7,392 Novo Nordisk shares in Q2 2026, an estimated $318K.
  • Novo Nordisk made up 0.01% of Regions Financial Corp's portfolio in Q2 2026, its #440 holding.
  • Regions Financial Corp first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • Regions Financial Corp's Novo Nordisk position peaked at $5.75M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Regions Financial Corp's 13F filing for Q2 2026, filed 10 Aug 2026.